

1 RENE L. VALLADARES
Federal Public Defender
2 Nevada Bar No. 11479
DAVID ANTHONY
3 Assistant Federal Public Defender
Nevada Bar No. 7978
4 David_Anthony@fd.org
BRAD D. LEVENSON
5 Assistant Federal Public Defender
California Bar No. 166073
6 Brad_Levenson@fd.org
7 Attorneys for Plaintiff Zane M. Floyd
8

9 UNITED STATES DISTRICT COURT
10 DISTRICT OF NEVADA

11 ZANE M. FLOYD,

12 Plaintiff,

13 v.

14 CHARLES DANIELS, Director, Nevada
Department of Corrections, et al.,

15 Defendants.
16
17
18
19
20
21
22
23

Case No. 3:21-cvv-00176-RFB-CLB

**MOTION TO COMPEL
COMPLIANCE WITH REQUESTS
FOR PRODUCTION AS TO
DEFENDANT ISHAN AZZAM**

(DEATH PENALTY CASE)

TABLE OF CONTENTS

| | |
|--|----|
| MEMORANDUM OF POINTS AND AUTHORITIES | 4 |
| I. INTRODUCTION | 4 |
| II. LEGAL AUTHORITY | 5 |
| III. ARGUMENT | 6 |
| A. The privileges claimed by Dr. Azzam should not prevent disclosure of the requested documents..... | 6 |
| 1. Dr. Azzam’s assertion of the deliberative process privilege is unpersuasive. | 7 |
| a) The Defendants have waived the privilege | 7 |
| b) Floyd’s need for disclosure outweighs any state interest in nondisclosure. | 11 |
| 2. Neither the work product doctrine nor the attorney-client privilege shield Dr. Azzam from disclosure of requested documents and providing testimony on the same. | 14 |
| B. Dr. Azzam’s conclusory statements concerning relevance are insufficient to justify nondisclosure..... | 17 |
| IV. CONCLUSION..... | 18 |

1 Plaintiff Zane Michael Floyd hereby moves, pursuant to Fed. R. Civ. P. 37(a),
2 for an order compelling defendant Ihsan Azzam, Chief Medical Officer of the State
3 of Nevada, to comply with his requests for production, to provide testimony, and
4 permit full disclosure of the requested documents, which is necessary for a full and
5 fair development of the material facts in this capital case. This motion is based upon
6 the attached memorandum of points and authorities and exhibits, the FRCP
7 37(a)(1) certification of counsel, and upon the entire file in this matter.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

MEMORANDUM OF POINTS AND AUTHORITIES

I. INTRODUCTION

Zane Floyd is currently challenging Nevada's execution protocol, arguing that any executions carried out under the protocol will constitute cruel and unusual punishment and violate his right to due process. As part of Floyd's claim, he challenges the drugs used in the execution as creating a substantial and unnecessary risk of causing unconstitutional pain and suffering. Under state law, the Director of the Nevada Department of Corrections (NDOC) purportedly chose the drugs to be used in the execution only after consultation with Dr. Azzam, the Chief Medical Officer for the state. NRS 176.355(2)(b).

On May 2, 2021, counsel for Floyd and Defendants held an initial discovery conference as required by Rule 26(f). On May 14, 2021, Defendant Azzam filed a privilege log, wherein he asserted the deliberative process privilege, and the attorney-client privilege, for twelve documents. ECF No. 65 (Dr. Azzam's privilege log, filed as Exhibit A filed under seal).¹ Thereafter, the parties continued to meet and confer regarding discovery and on June 3, 2021, entered into a stipulated protective order and confidentiality agreement for all sensitive documents obtained through discovery. ECF No. 87.

On June 23, 2021, the parties filed a proposed discovery schedule with this

¹ Mr. Floyd asserts on information and belief that at least some of the documents consist of Dr. Azzam's ultimate opinion of NDOC's 2018 midazolam protocol, a protocol potentially consisting of ketamine under consideration by the former NDOC Director James Dzurenda, and Dr. Azzam's ultimate opinion to Director Daniels with respect to the instant execution protocol. In particular, entry Nos. 1, 3-6, 10, and 12 may contain Dr. Azzam's ultimate opinion on the three protocols.

1 Court. Pursuant to that schedule, Floyd submitted his requests for production to
2 Defendant Azzam under Fed. R. Civ. P. 34, on June 30, 2021. Counsel for Defendant
3 Azzam returned their responses, including blanket objections to all of Floyd's RFPs,
4 on July 9, 2021. The parties met and conferred in an attempt to resolve the disputed
5 RFPs on July 20, 2021, but they could not come to an agreement. Attachment 1.
6 David Anthony and Brad Levenson participated for Mr. Floyd; and Crane
7 Pomerantz participated for Defendant Azzam.

8 This motion follows.

9 **II. LEGAL AUTHORITY**

10 The Federal Rules of Civil Procedure were meant to establish a system in
11 which discovery is self-executing. *Shuffle Master Inc. v. Progressive Games, Inc.*, 170
12 F.R.D. 166, 171 (D. Nev. 1996) (discussing the purpose of the certification
13 requirements of Fed. R. Civ. P. 37(a)(1)); *see also* Local Rule 26-6(c) (requiring
14 consultation between counsel before moving for motion to compel).

15 But, if attempts to obtain discovery become futile, the Federal Rules of Civil
16 Procedure permit a party to "move for an order compelling disclosure or discovery"
17 as long as that party attaches "a certification that the movant has in good faith
18 conferred or attempted to confer with the person or party failing to make disclosure
19 or discovery in an effort to obtain it without court action." Fed. R. Civ. P. 37(a)(1).
20 For purposes of the federal rules, "an evasive or incomplete disclosure, answer, or
21 response must be treated as a failure to disclose or respond." *Id.*

22 As established in the declaration provided by counsel for Floyd, good faith
23 efforts, although unsuccessful, have been made to confer with counsel for counsel for

1 Dr. Azzam in an effort to resolve this matter without court action. Now Floyd seeks
2 judicial intervention to resolve the disputes.

3 **III. ARGUMENT**

4 Dr. Azzam objected to twelve of Floyd's requests for production based on the
5 deliberative process privilege, work product doctrine, and attorney client privilege.²
6 He objected to an additional four requests based on relevance. None of the asserted
7 objections are valid. As a result, Plaintiff requests that the Court order Dr. Azzam
8 to produce the documents in dispute and to provide testimony concerning the same.

9 **A. The privileges claimed by Dr. Azzam should not prevent** 10 **disclosure of the requested documents.**

11 In response to requests two through thirteen, Dr Azzam repeats the identical
12 objection, that the requests "seek[] information protected from disclosure under the
13 deliberative process privilege, work product doctrine and/or the attorney-client
14 privilege."³ As an initial note, this blanket assertion of privilege is improper: "any
15 privilege objection should be specific with respect to documents or other
16 communications." *In re Imperial Corp. of Am.*, 174 F.R.D. 475, 477 (S.D. Cal. 1997).
17 However, Floyd also acknowledges that counsel for Dr. Azzam previously provided a
18 privilege log that connects the assertions of privilege to particular documents
19 withheld, and this motion is limited to those documents and any testimony
20 concerning those documents by Dr. Azzam. In any event, any assertion of privilege

21
22 ² See Ex. 26. While Dr. Azzam's response to the RFPs mentions the work product
23 privilege, the privilege log previously provided by counsel does not assert work
product protection as to any of the documents identified in the privilege log.

³ Ex.26.

1 should not shield the documents requested from disclosure.

2 **1. Dr. Azzam's assertion of the deliberative process**
 3 **privilege is unpersuasive.**

4 The deliberative process privilege “permits the government to withhold
 5 documents that reflect advisory opinions, recommendations and deliberations
 6 comprising part of a process by which government decisions and policies are
 7 formulated.” *FTC v. Warner Communications*, 742 F.2d 1156, 1161 (9th Cir. 1984)
 8 (citing *NLRB v. Sears, Roebuck & Co.*, 421 U.S. 132, 150–51 (1975)). To invoke the
 9 privilege the government must demonstrate that a document is “both pre-decisional
 10 and deliberative.”⁴

11 However, the deliberative process privilege is not absolute, and the existence
 12 of recognized exceptions will warrant disclosure. *In re McKesson Governmental*
 13 *Entities Average Wholesale Price Litig.*, 264 F.R.D. 595, 601 (N.D. Cal 2009). For
 14 example, a party may waive the privilege either by failing to properly or timely
 15 assert the privilege, or by voluntarily producing privileged documents. *McKesson*,
 16 264 F.R.D. at 599. Additionally, the privilege may be overcome if a litigant’s “need
 17 for the materials and the need for accurate fact-finding override the government’s
 18 interest in non-disclosure.” *Warner*, 742 F.2d at 1161.

19 **a) The Defendants have waived the privilege**

20 Dr. Azzam waived the deliberative process privilege for documents 1, 10, and

21
 22 ⁴ “A document may be considered predecisional if it was ‘prepared in order to assist
 23 an agency decisionmaker in arriving at his decision.’” *Assembly of California v.*
United States Department of Commerce, 968 F.2d 916, 921 (9th Cir. 1992). And a
 deliberative document details the “mental processes of decision-makers.” *Carter v.*
U.S. Dept. of Commerce, 307 F.3d 1084, 1090 (9th Cir. 2002).

12 in his privilege log, by failing to object and assert the privilege when NDOC disclosed documents detailing Dr. Azzam's ultimate opinion on the 2018 Midazolam protocol in its production log. *See* Ex. 27. Neither Dr. Azzam nor NDOC have designated that document as privileged or confidential under the protective order. ECF No. 87 at 3. As a result, Dr. Azzam waived the privilege for issues related to the selection and use of midazolam in NDOC's 2018 execution protocol. And Dr. Azzam and NDOC Defendants may not selectively disclose Azzam's ultimate opinion with respect to the midazolam protocol without providing disclosure of his ultimate opinions of the instant execution protocol. *Cf.* FRE 106. Otherwise, Defendants would be allowed to garble the truth by creating an inference that if Dr. Azzam approved of the midazolam protocol he must have also necessarily have approved of the current protocol. Dr. Azzam's ultimate opinion regarding the current protocol is relevant information, particularly given that he may have recommended against the protocol to the former NDOC Director, who declined to proceed with the execution of Scott Dozier, whereas Director Daniels may have gone against Dr. Azzam's recommendation.

Though the Ninth Circuit has not adopted a formal test to determine whether a party has inadvertently waived the deliberative process privilege, many courts in this Circuit have considered: "(1) the reasonableness of the precautions to prevent inadvertent disclosure; (2) the time taken to rectify the error; (3) the scope of discovery; (4) the extent of the disclosure; and (5) the 'overriding issue of fairness.'" *McKesson*, 264 F.R.D. at 599 (*quoting Eureka Financial Corp. v. Hartford Accident and Indemnity Co.*, 136 F.R.D. 179, 184 (E.D.Cal.1991)). Other courts apply the

1 more general waiver standard described in *Burlington Northern & Santa Fe Ry. v.*
2 *United States*, 408 F.3d 1142 (9th Cir. 2005), which focuses mainly on timely
3 assertion after inadvertent disclosure. Here, both the *Burlington* and *McKesson*
4 frameworks support a finding of waiver.

5 Each of the *McKesson* factors supports finding waiver. Dr. Azzam was
6 required to designate a document as protected within three days of disclosure as
7 required by the protective order. ECF No. 87 at 3. Counsel for Dr. Azzam was given
8 ample opportunities to object to any improper disclosure by NDOC in its production
9 log. However, it is the ultimate responsibility of Defendants, not Plaintiffs, to assert
10 privileges, and correct unintended disclosures, to avoid waiver or forfeiture of a
11 privilege objection.

12 Dr. Azzam's untimeliness in rectifying this disclosure also supports a finding
13 of forfeiture and waiver. Over sixty days have passed since NDOC provided its
14 production log, which means Dr. Azzam has had two months to assert the
15 deliberative process privilege for these documents, and he has failed to do so.
16 Moreover, only one week remains under FRCP 34(b)(2)(A) for Dr. Azzam to provide
17 all discovery sought by Floyd's RFPs. As a result, notions of fairness further
18 necessitate that this Court find Dr. Azzam waived any privilege for these
19 documents as well as any testimony concerning these matters *See Eureka*, 136
20 F.R.D. at 184-85 (concluding that fairness dictated waiver of privileged
21 communications considering the parties failure to assert the privilege and "the
22 stringent time constraint affecting th[e] discovery.").

23 Lastly, the extent of the disclosure here supports waiver. Where discovery is

1 sizable, thus making inadvertent waiver more excusable, privileged documents are
2 typically not waived. *See e.g., compare Lazar v. Mauney*, 192 F.R.D. 324, 330 (N.D.
3 GA 2000) (refusing to find waiver where among 1,000 documents three privileged
4 documents were disclosed), *with Local 851 of Int’l Bhd. of Teamsters v. Kuehne &*
5 *Napel Air Freight, Inc.*, 36 F.Supp.2d 127, 133 (E.D.N.Y. 1998) (finding a waiver of
6 privilege after a single privileged document was included as an exhibit with six
7 nonprivileged documents). Here, discovery has been on a relatively small scale with
8 respect to Dr. Azzam, making his failure to assert the privilege unreasonable.

9 Moreover, the small number of documents currently at issue in this case
10 further supports a finding of waiver under *Burlington*. When assessing whether an
11 asserted privilege is timely and therefore reasonable, the “magnitude of the
12 document production” is considered. *Burlington*, 408 F.3d at 1149. Here, the
13 discovery concerning Dr. Azzam is neither voluminous nor complex. *Contra*
14 *Coalition for a Sustainable Delta v. Koch*, No. 1:08-CV-00397, 2009 WL 3378974, at
15 *5 (E.D. Cal. Oct. 15, 2009) (finding defendant’s delayed assertion of privilege
16 timely and asserted “as soon as reasonably practicable” where 83,000 documents
17 were produced, and 4,200 emails were reviewed). Dr. Azzam only noted twelve
18 documents on his privilege log. Similarly, NDOC only identified twenty documents
19 on its privilege log and fifteen on its production log. In sum, given the small
20 universe of documents Dr. Azzam’s failure to designate the document disclosed by
21 NDOC as privileged supports a finding of forfeiture and waiver of any privilege
22 objection that it could have raised to prevent disclosure.

1 **b) Floyd’s need for disclosure outweighs any state**
2 **interest in nondisclosure.**

3 Even if waiver does not support disclosure, disclosure is still warranted as
4 the deliberative process privilege is not absolute. Disclosure is warranted, despite
5 the privilege, when the requesting party’s need outweighs the government’s interest
6 in nondisclosure. *Warner*, 742 F.2d at 1161. To make that weighing determination,
7 courts consider: “1) the relevance of the evidence; 2) the availability of other
8 evidence; 3) the government’s role in the litigation; and 4) the extent to which
9 disclosure would hinder frank and independent discussion regarding contemplated
10 policies and decisions.” *Id.* Each of these factors weighs in favor of disclosure.

11 Starting with relevance, the documents sought in requests two through
12 thirteen of Floyd’s RFPs are undoubtedly relevant to this litigation. Floyd is
13 challenging the constitutionality of NDOC’s execution protocol, including the lethal
14 drugs to be used, dosages, and sequence. Dr. Azzam may have directly contributed
15 to establishing the protocol by consulting with Director about the combination of
16 drugs to be used in Floyd’s execution. Because of this, Dr. Azzam’s communications,
17 opinions, and thoughts concerning the lethal drugs are extremely relevant and
18 directly at issue. Indeed, in cases such as this where the government’s decision-
19 making process is under scrutiny, discovery of otherwise privileged evidence is
20 necessary. *See United States v. Irvin*, 127 F.R.D. 169, 174 (C.D. Cal. 1989) (denying
21 a claim of deliberative process privilege where the government’s process was
22 essential to the litigation); *see also Greenpeace v. Nat’l Marine Fisheries Serv.*, 198
23 F.R.D. 540, 544 (W.D. Wash. 2000) (holding that “the [deliberative process] privilege

1 may be inapplicable where the agency's decision-making process is itself at issue.”).

2 Turning to the second *Warner* factor, disclosure is warranted as the evidence
3 Floyd seeks is not available elsewhere. The existence of other available evidence “is
4 perhaps the most important factor in determining whether the deliberative process
5 privilege should be overcome.” *N. Pacifica, LLC v. City of Pacifica*, 274 F. Supp. 2d
6 1118, 1124 (N.D. Cal. 2003). Here, because requests two through thirteen demand
7 all of Dr. Azzam's communications, research, and efforts exercised in consulting
8 with the Director regarding NDOC's execution protocol, the documents are
9 necessarily isolated to a single source, Dr. Azzam, and not available through any
10 nonparty. As a result, absent this Court's order requiring disclosure, Floyd has no
11 opportunity to obtain the documents and testimony essential to his litigation. *See*
12 *e.g., Warner*, 742 F.2d at 1161-62 (finding this factor did not support disclosure
13 where defendants were able to independently obtain the requested information).

14 Furthermore, like the first and second *Warner* factors, the third factor also
15 weighs in favor of production. It is well recognized that “[t]he fact that a
16 government entity's action is the focal point of litigation weighs against upholding
17 the deliberative process privilege.” *Thomas v. Cate*, 715 F. Supp. 2d 1012, 1028
18 (E.D. Cal. 2010). Here, Floyd's lawsuit directly implicates a government entity—
19 NDOC and Dr. Azzam in his official capacity, and specific departments and
20 department heads within the government. Because Dr. Azzam is an employee of the
21 State of Nevada, and the alleged actions occurred in the course of his official duties
22 as Chief Medical Officer of the State of Nevada, the government has a distinct role
23 in this litigation and thus disclosure of the requested documents is warranted.

1 Finally, the last *Warner* factor contemplates the result of disclosure, and
2 whether that exposure will have a “chilling effect.” *Desert Survivors v. U.S. Dep’t of*
3 *the Interior*, 231 F. Supp. 3d 368, 385 (N.D. Cal. 2017); *see also Thomas*, 715 F.
4 Supp. 2d at 1028 (describing the “chilling effect” as impeding government official’s
5 “willingness to freely explore possibilities or engage in internal debates”). Here, the
6 existence of a protective order eliminates any potential “chilling effect.” *See United*
7 *States v. W.R. Grace*, 455 F. Supp. 2d 1140, 1144–45 (D. Mont. 2006) (ordering
8 disclosure of documents previously withheld under the deliberative process privilege
9 because subsequent protective order adequately protected government’s interests).

10 In *W.R. Grace*, defendants filed a motion to compel discovery of documents
11 the government had refused to disclose based upon the deliberative process
12 privilege. Because there was a protective order in place which limited dissemination
13 of any “sensitive” document, the court granted the motion concluding that “the
14 protective order guarantees that designated documents will not be broadly
15 disseminated, which should serve to allay agency fears that the public will gain
16 access to their decision making processes, which is “the primary ‘evil’ the privilege
17 is designed to prevent.” *Id.* at 1144. Like the plaintiffs in *W.R. Grace*, Dr. Azzam
18 should not be allowed to withhold documents under the protection of the
19 deliberative process when the Court’s June 3, 2021 protective order provides the
20 same safeguards by shielding sensitive documents and testimony from public
21 disclosure. The protective order ensures that all communications related to Dr.
22 Azzam’s consultation with respect to the selection of execution drugs, participation
23 in developing the protocol, and discussions concerning that protocol between

1 government officials remain confidential, as only Floyd’s legal team will have access
2 to their contents.

3 Considering that Dr. Azzam’s interest in keeping his deliberative process
4 shielded has been addressed by the protective order, this factor, along with the
5 other *Warner* factors, demonstrate that Floyd’s need outweighs the government’s
6 concerns.

7 **2. Neither the work product doctrine nor the attorney-client**
8 **privilege shield Dr. Azzam from disclosure of requested**
9 **documents and providing testimony on the same.**

10 Dr. Azzam also claims that requests two through thirteen are protected by
11 the “work product doctrine and/or the attorney-client privilege.” He fails, however,
12 to provide any support whatsoever for these objections. As explained above, the
13 actual privilege log does not assert the work product privilege over the specific
14 documents so any assertion now of work product protection (in a blanket and non-
15 specific fashion in Dr. Azzam’s response to the RFPs) is untimely and therefore
16 waived. *E.g., Breed v. United States Dist. Ct.*, 542 F.2d 1114, 1115 (9th Cir. 1976).

17 A party claiming either attorney-client privilege or work product protection
18 must make several showings to justify nondisclosure. A government official
19 claiming attorney-client privilege must establish that each privileged document
20 resulted in: “(1) a communication between client and counsel, which (2) was
21 intended to be and was in fact kept confidential, and (3) made for the purpose of
22 obtaining or providing legal advice.” *Fisher v. United States*, 425 U.S. 391, 403
23 (1976); *see also Thomas*, 715 F. Supp. 2d at 1045. The privilege “protects only those
disclosures necessary to obtain informed legal advice which might not have been

1 made absent the privilege,” it does not safeguard communications merely because
2 an attorney was present. *Fisher*, 425 U.S. at 403.

3 Similarly, the work product doctrine shields “materials prepared by [or for]
4 an attorney in anticipation of litigation.” *United States v. Bergonzi*, 216 F.R.D. 487,
5 494 (N.D. Cal. 2003) (citations omitted). To fall under the work product doctrine,
6 documents must: “(1) be prepared in anticipation of litigation or for trial and (2) be
7 prepared by or for another party or by or for that other party's
8 representative.” *United States v. Richey*, 632 F.3d 559, 567 (9th Cir. 2011) (citation
9 and quotation marks omitted). In both instances, the party asserting the privilege is
10 responsible for establishing that it applies. *Id.* at 566.

11 Dr. Azzam failed to satisfy either burden for requests two through thirteen.
12 None of the requests ask for legal documents or documents which could be
13 construed as communications between Dr. Azzam and his counsel. Each request
14 focuses solely on gaining information related to the selection of execution drugs, Dr.
15 Azzam’s statutorily mandated participation in developing the protocol, and
16 discussions concerning that protocol between government officials, not Dr. Azzam
17 and his attorneys. For example, Dr. Azzam asserted attorney-client privilege in
18 response to request number 10, which seeks, among other things, documents
19 concerning research, studies, and literature reviewed. Likewise, request number 4
20 asks for documents detailing Dr. Azzam’s recommendations to NDOC regarding the
21 current execution protocol. This request is clearly not seeking any legal advice and
22 Dr. Azzam fails to demonstrate otherwise. And the privilege log similarly fails to
23 justify assertion of the privilege here, as it includes imprecise and general

1 descriptions of documents that are characterized as attorney-client communications
2 but were not made between an attorney and Dr. Azzam.

3 Finally, third parties were included in some of these communications
4 (document nos. 1 and 2), another factor which would waive the privilege and compel
5 disclosure of the privileged documents. *See In re Pac. Pictures Corp.*, 679 F.3d 1121,
6 1127-28 (9th Cir. 2012) ([V]oluntarily disclosing privileged documents to third
7 parties will generally destroy the [attorney-client] privilege.”).

8 Similar reasons undermine Dr. Azzam’s assertion of the work product
9 privilege. None of the RFPs request any information or documents that were
10 created in anticipation of litigation. And, although Dr. Azzam objected to RFPs 2
11 through 13 partly based on the work product doctrine, he failed to invoke that
12 privilege for any documents in his privilege log. *See* ECF No. 65 (under seal). To the
13 extent that this Court finds the work product doctrine properly asserted, Dr. Azzam
14 still fails to show that the documents noted in the privilege log were “prepared in
15 anticipation of litigation.” Documents 9 and 11 are the only ones that even mention
16 “litigation.” Moreover, based on Dr. Azzam’s own description the majority of the
17 items identified in the privilege log were not “prepared in anticipation of litigation,”
18 rather, the communications took place due to Dr. Azzam’s statutory duty to consult
19 with the Director regarding drug combination to be used in Nevada’s execution
20 protocol.

21 Accordingly, Dr. Azzam cannot invoke the attorney-client privilege or the
22 work product doctrine to justify nondisclosure. Alternatively, to the extent any
23 information is subject to the attorney client privilege, the privileged portions should

1 be segregated from the non-privileged portions and the remainder should be
2 disclosed.

3 **B. Dr. Azzam’s conclusory statements concerning relevance**
4 **are insufficient to justify nondisclosure.**

5 Dr. Azzam objected to four of Floyd’s requests for production on relevancy
6 grounds, numbers two, six, seven, and eleven.⁵ For each of the requests, Dr.
7 Azzam’s objection consisted of a single conclusory statement: “Dr. Azzam also
8 objects to the request to the extent that it seeks information that is not relevant and
9 not reasonably likely to lead to relevant and admissible evidence.” Ex. 26. This is
10 not a proper objection. “The party resisting discovery must specifically detail the
11 reasons why each request is irrelevant or otherwise objectionable, and may not rely
12 on boilerplate, generalized, conclusory, or speculative arguments.” *Big City Dynasty*
13 *v. FP Holdings, L.P.*, 336 F.R.D. 507, 510 (D. Nev. 2020); *see V5 Techs. v. Switch,*
14 *Ltd.*, 334 F.R.D. 297, 301 (D. Nev. 2019). And because these requests seek
15 information directly related to the selection of execution drugs, Dr. Azzam’s
16 ultimate opinion with respect to the combination of drugs is obviously relevant. *See*
17 *Fed. R. Civ. P. 26(b)(1)* (allowing “discovery regarding any nonprivileged matter
18 that is relevant to any party’s claim or defense and proportional to the needs of the
19 case”). The prospect that the Director intends to go forward with an execution
20 protocol that is not supported by the only medical official to whom he is statutorily
21 required to consult is relevant information that Floyd is entitled to know and to

22
23 ⁵ Dr. Azzam added that he had no responsive documents for request numbers six
and seven. Floyd nonetheless addresses those requests here, in case additional
documents are discovered in the future.

1 elicit testimony from Dr. Azzam regarding the same.

2 **IV. CONCLUSION**

3 Based on the foregoing, Floyd respectfully requests that this Court grant his
4 Motion to Compel and order Dr. Azzam to comply with his requests for production
5 and to provide testimony on these subjects. Disclosure of the documents requested
6 in request numbers 2 through 13 is warranted as Floyd's need for the information
7 outweighs the government's interest in keeping its deliberative process secret and
8 NDOC and Dr. Azzam have already waived disclosure with respect to all issues
9 relating to Dr. Azzam's ultimate opinion of the protocols. Moreover, Dr. Azzam has
10 not satisfied his burden, under the attorney client privilege, to avoid disclosure of
11 documents. Finally, Dr. Azzam has failed to demonstrate that requests two, six,
12 seven, and eleven are irrelevant to support his failure to disclose them.

13 Dated this 23rd day of July, 2021.

14 Respectfully submitted,

15 Rene L. Valladares
16 Federal Public Defender

17 /s/ David Anthony
18 DAVID ANTHONY
Assistant Federal Public Defender

19 /s/ Brad D. Levenson
20 BRAD D. LEVENSON
Assistant Federal Public Defender

CERTIFICATE OF SERVICE

In accordance with the LR IC 4-1(a) of the Local Rules of Practice, the undersigned hereby certifies that on this 23rd day of July, 2021, a true and correct copy of the foregoing MOTION TO COMPEL COMPLIANCE WITH REQUESTS FOR PRODUCTION AS TO DEFENDANT ISHAN AZZAM, was filed electronically with the United States District Court. Electronic service of the foregoing document shall be made in accordance with the master service list as follows:

D. Randall Gilmer
Chief Deputy Attorney General
Office of the Nevada Attorney General
drgilmer@ag.nv.gov
Crane Pomerantz, Esq.
Nadia Ahmed, Esq.
SKLAR WILLIAMS PLLC
cpomerantz@sklar-law.com
nahmed@sklar-law.com

/s/ Sara Jelinek
An Employee of the Federal Public
Defenders Office, District of Nevada